OrganoTherapeutics uses cutting-edge human-specific midbrain organoids for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen new molecules on our proprietary organoids which mimic faithfully the human Parkinson’s disease pathology. OrganoTherapeutics aims at developing new drug candidates against Parkinson’s disease which are tested in state-of-the art 3D patient models. OrganoTherapeutics has developed first own proprietary drug candidates and has access to attractive libraries for further screening.

OrganoTherapeutics

Org chart

Teams

Offices

OrganoTherapeutics

Org chart

Teams

Offices

Related companies